Q-omics provides the consensus-scored KCNQ4 profile across patient tissues and cancer cell-line models. KCNQ4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, KCNQ4 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, KCNQ4 RNA expression shows 15,507 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SKCM, BLCA, and ACC as cancer lineages where KCNQ4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNQ4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNQ4 survival associations across molecular data types. KCNQ4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNQ4 RNA expression–survival associations across cancer types. High KCNQ4 expression shows unfavorable associations in SKCM, ACC, LIHC and UCEC, but favorable associations in HNSC and OV. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for KCNQ4 RNA expression.
This table summarizes KCNQ4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for KCNQ4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNQ4 shows lower tumor expression in BLCA, THCA, BRCA, UCEC and HNSC and higher tumor expression in CHOL. The BLCA box plot shows higher KCNQ4 RNA expression in normal versus tumor tissue (log2 FC = −3.512, t-test p < 0.001).
This table shows molecular features associated with KCNQ4 in patient tissues and cancer cell lines. In patient samples, KCNQ4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNQ4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
